Update of the MDS research criteria for prodromal Parkinson's disease

  title={Update of the MDS research criteria for prodromal Parkinson's disease},
  author={Sebastian Heinzel and Daniela Berg and Thomas Gasser and Honglei Chen and Chun W Yao and Ronald B. Postuma},
  journal={Movement Disorders},
The MDS Research Criteria for Prodromal PD allow the diagnosis of prodromal Parkinson's disease using an evidence‐based conceptual framework, which was designed to be updated as new evidence becomes available. New prospective evidence of predictive values of risk and prodromal markers published since 2015 was reviewed and integrated into the criteria. Many of the predictive values (likelihood ratios, LR) remain unchanged. The positive likelihood ratio notably increase for olfactory loss and… 
Bayesian network modeling of risk and prodromal markers of Parkinson's disease
The use of artificial intelligence (AI) to model and understand interdependencies between PD risk and prodromal markers, which are so far not accounted for in PD prediction models, demonstrates the potential of modern AI approaches (specifically BNs) in two ways.
Research criteria for the diagnosis of prodromal dementia with Lewy bodies
This work proposes operationalized diagnostic criteria for probable and possible mild cognitive impairment with Lewy bodies, which are intended for use in research settings pending validation for Use in clinical practice and are compatible with current criteria for other prodromal neurodegenerative disorders including Alzheimer and Parkinson disease.
Prodromal Cognitive Deficits and the Risk of Subsequent Parkinson’s Disease
Background: There is growing interest in identifying individuals who are in the prodromal phase of Parkinson’s disease (PD), as these individuals are potentially suitable for inclusion in
Diagnosing multiple system atrophy at the prodromal stage
Building on similar approaches as for PD and DLB, features on history-taking, clinical examination, and ancillary clinical testing that can predict the likelihood of an individual developing MSA are identified, while also distinguishing it from PD andDLB.
Heterogeneity of prodromal Parkinson symptoms in siblings of Parkinson disease patients
Siblings showed a heterogeneous distribution of prodromal PD markers and probability, and additional parameters, including strong disease markers, should be investigated to verify if these results depend on validity and sensitivity of prodROMal PD criteria, or if siblings’ risk is not elevated.
Cognition in prodromal Parkinson's disease.
The Multiple Sclerosis Prodrome: Evidence to Action
This Perspective provides a succinct overview of the recent advances in the understanding of the MS prodrome and current key challenges and suggests how best to move from the rapidly growing evidence to research-related action is critical.
Late life psychotic features in prodromal Parkinson's disease.
Clinical and Imaging Markers of Prodromal Parkinson's Disease
The approach to prodromal PD is reviewed, with an emphasis on clinical and imaging markers and results from the neuroimaging study, a retrospective evaluation of a cohort of 39 participants who underwent DAT-SPECT scan as part of their follow up.


Prodromal Markers in Parkinson’s Disease: Limitations in Longitudinal Studies and Lessons Learned
The observed heterogeneity of studies, limitations and analyses might be addressed in future longitudinal studies using a, yet to be established, modular minimal set of assessments improving comparability of findings and enabling data sharing and combined analyses across studies.
Structural connectome alterations in prodromal and de novo Parkinson's disease patients.
Neuroimaging in pre-motor Parkinson's disease☆
Meta‐analysis of 123I‐MIBG cardiac scintigraphy for the diagnosis of Lewy body–related disorders
A meta‐analysis of the literature and an assessment of the utility of 123I‐metaiodobenzylguanidine cardiac scintigraphy for the diagnosis of dementia with Lewy bodies and Parkinson's disease found it can accurately distinguish between 2 movement disorders, Parkinson's Disease and multiple system atrophy, and between 2 common causes of dementia, Alzheimer's disease and dementia withLewy bodies.
Association Between Poor Cognitive Functioning and Risk of Incident Parkinsonism: The Rotterdam Study
Poor cognitive functioning is associated with an increased risk of incident parkinsonism, including probable PD and the findings suggest that cognitive dysfunction can be considered a sign of prodromal PD.
Familial aggregation of Parkinson’s disease and coaggregation with neuropsychiatric diseases: a population-based cohort study
First-degree relatives of Parkinson’s disease patients are more likely to develop PD and other neuropsychiatric diseases.
New Clinical Subtypes of Parkinson Disease and Their Longitudinal Progression: A Prospective Cohort Comparison With Other Phenotypes.
It is recommended to screen patients with Parkinson disease for mild cognitive impairment, orthostatic hypotension, and RBD even at baseline visits to identify a diffuse/malignant subgroup of patients with PD for whom the most rapid progression rate could be expected.
Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease.
Findings from this selected group of patients with PD demonstrated that parkinsonian motor features can occur in the absence of Lewy bodies, however, LB pathology in LRRK2-related PD may be a marker for a broader parkinsonia symptom complex including cognitive impairment.
Inflammatory bowel disease increases the risk of Parkinson’s disease: a Danish nationwide cohort study 1977–2014
This nationwide, unselected, cohort study shows a significant association between IBD and later occurrence of PD, which is consistent with recent basic scientific findings of a potential role of GI inflammation in development of parkinsonian disorders.